Hansa

Hansa Biopharma publishes 2023 Annual and Sustainability Reports

Retrieved on: 
Thursday, March 21, 2024
Certification, Culture, Crigler–Najjar syndrome, Science, Partnership, Patient, Neutron, Hansa, Duchenne muscular dystrophy, Kidney transplantation, Commercial, Syndrome, GBS, Clinical trial, Therapy, Drug development, Sarepta Therapeutics, Safety, Pharmacokinetics, ANCA, DMD, Pharmaceutical industry

LUND, Sweden, March 21, 2024 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports. In 2023, the company made solid progress in both Commercial and R&D priorities and continued its journey to become a default sustainable organization.

Key Points: 
  • LUND, Sweden, March 21, 2024 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports.
  • Peter Nicklin, Chairman of the Board, Hansa Biopharma, said: "2023 was another important year for Hansa Biopharma.
  • Søren Tulstrup, President and CEO, Hansa Biopharma, said: "In 2023, the Company's focus remained firmly on advancing cutting-edge science and delivering new treatments in areas of high unmet need.
  • This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act.

Hansa Biopharma publishes 2023 Annual and Sustainability Reports

Retrieved on: 
Thursday, March 21, 2024
Certification, Culture, Crigler–Najjar syndrome, Science, Partnership, Patient, Neutron, Hansa, Duchenne muscular dystrophy, Kidney transplantation, Commercial, Syndrome, GBS, Clinical trial, Therapy, Drug development, Sarepta Therapeutics, Safety, Pharmacokinetics, ANCA, DMD, Pharmaceutical industry

LUND, Sweden, March 21, 2024 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports. In 2023, the company made solid progress in both Commercial and R&D priorities and continued its journey to become a default sustainable organization.

Key Points: 
  • LUND, Sweden, March 21, 2024 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced the publication of its 2023 Annual and Sustainability Reports.
  • Peter Nicklin, Chairman of the Board, Hansa Biopharma, said: "2023 was another important year for Hansa Biopharma.
  • Søren Tulstrup, President and CEO, Hansa Biopharma, said: "In 2023, the Company's focus remained firmly on advancing cutting-edge science and delivering new treatments in areas of high unmet need.
  • This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act.

Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer

Retrieved on: 
Thursday, February 22, 2024
CFO, MD, SVP, Growth, Executive Committee, Hansa, University, Therapy, Information services, Management

LUND, Sweden, Feb. 22, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced the appointment of Evan Ballantyne as Chief Financial Officer (CFO), effective 1 March 2024.

Key Points: 
  • LUND, Sweden, Feb. 22, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced the appointment of Evan Ballantyne as Chief Financial Officer (CFO), effective 1 March 2024.
  • As CFO, Mr. Ballantyne will be responsible for developing and implementing the Company's corporate financial strategy and activities including financial reporting and investor relations (IR).
  • Most recently, Mr. Ballantyne was Senior Vice President, Chief Financial Officer at Gain Therapeutics, Inc. (Gain), a US based biotech company.
  • Søren Tulstrup, President and CEO, Hansa Biopharma said, "I am thrilled to welcome Evan to Hansa Biopharma at this pivotal and exciting time.

Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer

Retrieved on: 
Thursday, February 22, 2024
CFO, MD, SVP, Growth, Executive Committee, Hansa, University, Therapy, Information services, Management

LUND, Sweden, Feb. 22, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced the appointment of Evan Ballantyne as Chief Financial Officer (CFO), effective 1 March 2024.

Key Points: 
  • LUND, Sweden, Feb. 22, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced the appointment of Evan Ballantyne as Chief Financial Officer (CFO), effective 1 March 2024.
  • As CFO, Mr. Ballantyne will be responsible for developing and implementing the Company's corporate financial strategy and activities including financial reporting and investor relations (IR).
  • Most recently, Mr. Ballantyne was Senior Vice President, Chief Financial Officer at Gain Therapeutics, Inc. (Gain), a US based biotech company.
  • Søren Tulstrup, President and CEO, Hansa Biopharma said, "I am thrilled to welcome Evan to Hansa Biopharma at this pivotal and exciting time.

Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference

Retrieved on: 
Saturday, January 6, 2024
Marketing, Repeat, Conference, Partnership, Kidney transplantation, Trial of the century, Sarepta Therapeutics, DMD, Imlifidase, Growth, ANCA, Enzyme, Patient, Duchenne muscular dystrophy, Hansa, Immunoglobulin G, Neutron, Pharmaceutical industry

Søren Tulstrup, President and CEO, Hansa Biopharma said: "Hansa enters 2024 in a strong position to successfully execute on our key priorities.

Key Points: 
  • Søren Tulstrup, President and CEO, Hansa Biopharma said: "Hansa enters 2024 in a strong position to successfully execute on our key priorities.
  • We also continue to expand access to imlifidase for highly sensitized kidney transplant patients through a new commercial partnership with NewBridge in the MENA region.
  • Management will be available for meetings in San Francisco during the J.P. Morgan Conference week, January 8-11, 2024.
  • Susan Noonan is coordinating the schedule on behalf of Hansa Biopharma and can be reached at [email protected] .

Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference

Retrieved on: 
Saturday, January 6, 2024
Marketing, Repeat, Conference, Partnership, Kidney transplantation, Trial of the century, Sarepta Therapeutics, DMD, Imlifidase, Growth, ANCA, Enzyme, Patient, Duchenne muscular dystrophy, Hansa, Immunoglobulin G, Neutron, Pharmaceutical industry

Søren Tulstrup, President and CEO, Hansa Biopharma said: "Hansa enters 2024 in a strong position to successfully execute on our key priorities.

Key Points: 
  • Søren Tulstrup, President and CEO, Hansa Biopharma said: "Hansa enters 2024 in a strong position to successfully execute on our key priorities.
  • We also continue to expand access to imlifidase for highly sensitized kidney transplant patients through a new commercial partnership with NewBridge in the MENA region.
  • Management will be available for meetings in San Francisco during the J.P. Morgan Conference week, January 8-11, 2024.
  • Susan Noonan is coordinating the schedule on behalf of Hansa Biopharma and can be reached at [email protected] .

Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation

Retrieved on: 
Thursday, December 14, 2023
DSA, Patient, AMR, Hansa, Imlifidase, Vaccine, Medical imaging

LUND, Sweden, Dec. 14, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced full results from the 16-HMedIdeS-12 phase 2 trial in patients with antibody mediated rejection (AMR) episodes following a kidney transplant demonstrating that imlifidase significantly reduced donor-specific antibodies (DSAs) within the first five days of treatment.

Key Points: 
  • In the trial, the primary endpoint was the maximum reduction in DSA level at any time point during the 5 days following the start of treatment.
  • Patients treated with imlifidase demonstrated a statistically significant reduction of DSAs by 94.4% compared to a 35.6% (p-value:
  • The secondary endpoint investigated overall kidney function following treatment.
  • This is an important step in understanding how imlifidase may benefit patients with AMR.

Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation

Retrieved on: 
Thursday, December 14, 2023
DSA, Patient, AMR, Hansa, Imlifidase, Vaccine, Medical imaging

LUND, Sweden, Dec. 14, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), today announced full results from the 16-HMedIdeS-12 phase 2 trial in patients with antibody mediated rejection (AMR) episodes following a kidney transplant demonstrating that imlifidase significantly reduced donor-specific antibodies (DSAs) within the first five days of treatment.

Key Points: 
  • In the trial, the primary endpoint was the maximum reduction in DSA level at any time point during the 5 days following the start of treatment.
  • Patients treated with imlifidase demonstrated a statistically significant reduction of DSAs by 94.4% compared to a 35.6% (p-value:
  • The secondary endpoint investigated overall kidney function following treatment.
  • This is an important step in understanding how imlifidase may benefit patients with AMR.

Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487

Retrieved on: 
Monday, October 9, 2023
Pharmacokinetics, Male, Enzyme, Antibody, Female, Hansa, Immunoglobulin G, Safety, Transplant, Flare, Repeat, Fragment antigen-binding, PD, Neutron, Patient, Pharmaceutical industry

LUND, Sweden, Oct. 9, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced high-level results from NICE-01, the first-in-human trial for HNSA-5487. Results showed the molecule was safe and well tolerated. Fast and complete depletion of immunoglobulin G (IgG) antibodies was observed at increasing doses in all subjects. Pharmacokinetics (PK) was in line with expectations and pharmacodynamics (PD) (efficacy on IgG cleavage) showed a fast and complete cleavage of IgG to F(ab')2- and Fc-fragments with increasing doses.

Key Points: 
  • LUND, Sweden, Oct. 9, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced high-level results from NICE-01, the first-in-human trial for HNSA-5487.
  • Fast and complete depletion of immunoglobulin G (IgG) antibodies was observed at increasing doses in all subjects.
  • Søren Tulstrup, President and CEO, Hansa Biopharma said, "This is encouraging data as we continue to explore the potential for HNSA-5487 and better understand how this powerful, new enzyme could benefit patients and clinicians.
  • This analysis will serve as key input in determining the further clinical development program, including selection of indications.

Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487

Retrieved on: 
Monday, October 9, 2023
Pharmacokinetics, Male, Enzyme, Antibody, Female, Hansa, Immunoglobulin G, Safety, Transplant, Flare, Repeat, Fragment antigen-binding, PD, Neutron, Patient, Pharmaceutical industry

LUND, Sweden, Oct. 9, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced high-level results from NICE-01, the first-in-human trial for HNSA-5487. Results showed the molecule was safe and well tolerated. Fast and complete depletion of immunoglobulin G (IgG) antibodies was observed at increasing doses in all subjects. Pharmacokinetics (PK) was in line with expectations and pharmacodynamics (PD) (efficacy on IgG cleavage) showed a fast and complete cleavage of IgG to F(ab')2- and Fc-fragments with increasing doses.

Key Points: 
  • LUND, Sweden, Oct. 9, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced high-level results from NICE-01, the first-in-human trial for HNSA-5487.
  • Fast and complete depletion of immunoglobulin G (IgG) antibodies was observed at increasing doses in all subjects.
  • Søren Tulstrup, President and CEO, Hansa Biopharma said, "This is encouraging data as we continue to explore the potential for HNSA-5487 and better understand how this powerful, new enzyme could benefit patients and clinicians.
  • This analysis will serve as key input in determining the further clinical development program, including selection of indications.